Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance
Background Sacituzumab govitecan is an antibody–drug conjugate that delivers SN-38, an active metabolite of irinotecan, to the target molecule, trophoblast cell-surface antigen 2 (Trop-2). It is a promising drug for triple-negative breast cancer and is anticipated to be effective for luminal breast...
Saved in:
Published in | Breast cancer (Tokyo, Japan) Vol. 29; no. 6; pp. 1076 - 1087 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Singapore
Springer Nature Singapore
01.11.2022
Springer |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!